From June 2025, GPs are able to prescribe Mounjaro to a very narrow cohort: people with a BMI of 40 or above, plus at least four out of five serious weight-related conditions including type 2 diabetes, cardiovascular disease, hypertension, dyslipidaemia and sleep apnoea.
This equates to just 220,000 people over three years, a fraction of the 3.4 million who would meet NICE’s broader...